DelveInsight’s, “Endometrial Cancer Pipeline Insight, 2026” report provides comprehensive insights about 50+ companies and 55+ pipeline drugs in Endometrial Cancer pipeline landscape. It covers the Endometrial Cancer pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Endometrial Cancer therapeutics assessment by product type, stage, Endometrial Cancer route of administration, and Endometrial Cancer molecule type. It further highlights the inactive pipeline products in this space.

Stay ahead in understanding the Endometrial Cancer Treatment Landscape @ https://www.delveinsight.com/sample-request/endometrial-cancer-pipeline-insight

Key Takeaways from the Endometrial Cancer Pipeline Report

• On May 28, 2026- Daiichi Sankyo conducted a phase 3 study to evaluate the efficacy and safety of T-DXd versus SoC chemotherapy with or without radiotherapy as adjuvant treatment in participants with HER2-expressing (IHC 3+/2+) endometrial cancer. Participants will be randomized 1:1 to either T-DXd or SoC chemotherapy. The primary objective will assess disease-free survival as assessed radiographically by BICR or by histopathologic confirmation of disease recurrence per local assessment.
• On May 22, 2026- Merck Sharp & Dohme LLC conducted a phase 3 study is to learn if people who receive sac-TMT with pembrolizumab live longer and without the cancer getting worse compared to people who receive pembrolizumab alone.
• On May 20, 2026- AstraZeneca initiated a Phase III, 2-arm, randomized, open label, multicenter, global study assessing the efficacy and safety of puxitatug samrotecan compared to physician’s choice of chemotherapy (doxorubicin or paclitaxel) in participants with B7-H4 selected advanced/metastatic EC that progressed following platinum based chemotherapy and anti-PD-1/anti-PD-L1 therapy.
• On May 20, 2026- BioNTech SE announced a phase III study is divided into two cohorts (Cohort 1 and Cohort 2), to which participants will be enrolled based on the amount of human epidermal growth factor receptor 2 (HER2) in their tumor sample.
• DelveInsight’s Endometrial Cancer pipeline report depicts a robust space with 50+ active players working to develop 55+ pipeline therapies for Endometrial Cancer treatment.
• The leading Endometrial Cancer Companies such as Carisma Therapeutics, Eli Lilly and Company, Karyopharm Therapeutics, NETRIS Pharma, TORL Biotherapeutics, Compugen, 3D Medicines, Chimerix, Evergreen Therapeutics, Acrivon Therapeutics, Eisai, Xadcera Biopharmaceutical (Suzhou) Co., Ltd., Huabo Biopharm Co., Ltd., Multitude Therapeutics, Context Therapeutics and others.
• Promising Endometrial Cancer Pipeline Therapies such as Ridaforolimus, Lenvatinib, BN83495, Megestrol Acetate (MA), brachytherapy, arzoxifene hydrochloride, Selinexor, Letrozole, ONC201, AEZS-108 / zoptarelin doxorubicin, doxorubicin, oxaliplatin, 5 FU, and others.

Gain in-depth knowledge of key clinical trials, emerging drugs, and market opportunities @ Endometrial Cancer Clinical Trials Assessment

Endometrial Cancer Overview

Endometrial cancer, originating from the inner lining of the uterus (endometrium), stands as the most prevalent gynecologic malignancy in developed nations, with its incidence on the rise. This increase is attributed to factors such as aging populations and escalating obesity rates. The majority of cases are diagnosed in postmenopausal women, with abnormal uterine bleeding serving as the most common presenting symptom. Early detection is common due to this symptom, leading to diagnoses at initial stages where treatment outcomes are more favorable.

Endometrial Cancer Emerging Drugs Profile

• Selinexor: Karyopharm Therapeutics

Selinexor (XPOVIO) is a first-in-class, oral exportin 1 (XPO1) inhibitor. XPOVIO functions by selectively binding to and inhibiting the nuclear export protein XPO1. The drug is being explored as a maintenance therapy for patients with advanced or recurrent endometrial cancer, particularly those with TP53 wild-type tumors. This approach is based on findings from the Phase III SIENDO study, which has shown promising results in improving progression-free survival (PFS) for this specific patient population. Currently it is being investigated in Phase III stage of development for the treatment of patients with Endometrial Cancer.

• Abemaciclib: Eli Lilly and Company

Abemaciclib, developed by Eli Lilly, is showing promising clinical activity in combination with hormonal therapies for recurrent estrogen receptor (ER)-positive endometrioid endometrial cancer (EEC). In a phase 2 trial, abemaciclib plus hormonal therapy achieved a clinical benefit rate of 67% in EEC patients, with partial and complete responses observed and a median progression-free survival (PFS) around 6.1 months. Another study combining abemaciclib with letrozole demonstrated a 30% objective response rate and a median PFS of 9.1 months, with durable tumor shrinkage or stabilization in 75% of patients. Adding metformin to this combination further improved outcomes, inducing deeper and more durable responses by targeting multiple cancer pathways including estrogen receptor, CDK4/6, and PI3K. These findings support abemaciclib plus hormonal therapy as a promising treatment approach for recurrent ER-positive endometrial cancer, with ongoing trials confirming safety and efficacy.

• NP137: NETRIS Pharma

NP137 is a humanized monoclonal antibody (IgG1) targeting netrin-1, a protein overexpressed in a large proportion of human cancers and associated with disease severity and resistance to therapy. By blocking netrin-1, NP137 is designed to restore apoptosis and reverse epithelial-to-mesenchymal transition (EMT), addressing critical mechanisms of resistance that limit the effectiveness of immune checkpoint inhibitors. Preclinical and early clinical studies have shown that NP137 has anti-cancer effects both as a monotherapy and in combination with chemotherapy or immunotherapy, with a favorable safety profile. According to the company’s pipeline the drug is in the Phase II stage of development for the treatment of patients with Endometrial Cancer.

• CT-0508: Carisma Therapeutics

CT-0508 is a human epidermal growth factor receptor 2 (HER2) targeted chimeric antigen receptor macrophage (CAR-M). It is being evaluated in a landmark Phase I multi-center clinical trial that focuses on patients with recurrent or metastatic HER2-overexpressing solid tumors whose cancers are not eligible for treatment with currently available HER2-targeted therapies or who do not respond to treatment. The trial is enrolling participants who have tumors of any anatomical origin, but with the commonality of overexpressing the HER2 receptor on the cell surface, which is the target for our CAR-M. The Phase 1 clinical trial is first-of-its-kind, marking the first time that genetically engineered macrophages are being studied in humans. The trial continues to enroll patients at seven clinical sites in the U.S., including (i) the University of Pennsylvania Abramson Cancer Center, (ii) the University of North Carolina Lineberger Comprehensive Cancer Center, (iii) the City of Hope National Medical Center, (iv) the MD Anderson Cancer Center, (v) the Sarah Cannon Cancer Research Institute, (vi) Oregon Health & Science University and (vii) Fred Hutchinson Cancer Center.

Uncover critical updates on therapeutic innovations and their potential impact on patients and the healthcare industry @ Endometrial Cancer Unmet Needs

The Endometrial Cancer Pipeline Report Provides Insights into

• The report provides detailed insights about companies that are developing therapies for the treatment of Endometrial Cancer with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Endometrial Cancer Treatment.
• Endometrial Cancer Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Endometrial Cancer Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Endometrial Cancer market

Endometrial Cancer Companies

Carisma Therapeutics, Eli Lilly and Company, Karyopharm Therapeutics, NETRIS Pharma, TORL Biotherapeutics, Compugen, 3D Medicines, Chimerix, Evergreen Therapeutics, Acrivon Therapeutics, Eisai, Xadcera Biopharmaceutical (Suzhou) Co., Ltd., Huabo Biopharm Co., Ltd., Multitude Therapeutics, Context Therapeutics and others.

Endometrial Cancer pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Subcutaneous
• Intravenous
• Oral
• Intramuscular

Endometrial Cancer Products have been categorized under various Molecule types such as

• Small molecules
• Natural metabolites
• Monoclonal antibodies

See the latest progress in drug development and clinical research @ Endometrial Cancer Market Drivers and Barriers, and Future Perspectives

Scope of the Endometrial Cancer Pipeline Report

• Coverage- Global
• Endometrial Cancer Companies- Carisma Therapeutics, Eli Lilly and Company, Karyopharm Therapeutics, NETRIS Pharma, TORL Biotherapeutics, Compugen, 3D Medicines, Chimerix, Evergreen Therapeutics, Acrivon Therapeutics, Eisai, Xadcera Biopharmaceutical (Suzhou) Co., Ltd., Huabo Biopharm Co., Ltd., Multitude Therapeutics, Context Therapeutics and others.
• Endometrial Cancer Pipeline Therapies- Ridaforolimus, Lenvatinib, BN83495, Megestrol Acetate (MA), brachytherapy, arzoxifene hydrochloride, Selinexor, Letrozole, ONC201, AEZS-108 / zoptarelin doxorubicin, doxorubicin, oxaliplatin, 5 FU, and others.
• Endometrial Cancer Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
• Endometrial Cancer Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

Access the Full Endometrial Cancer Pipeline Analysis Today! @ Endometrial Cancer Drugs and Companies

Table of Contents

1. Introduction
2. Executive Summary
3. Endometrial Cancer: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Endometrial Cancer – DelveInsight’s Analytical Perspective
7. Late Stage Products (Phase III)
8. Selinexor: Karyopharm Therapeutics
9. Mid Stage Products (Phase II)
10. Abemaciclib: Eli Lilly and Company
11. Early Stage Products (Phase I/II)
12. CT-0508: Carisma Therapeutics
13. Preclinical and Discovery Stage Products
14. Drug Name: Company Name
15. Inactive Products
16. Endometrial Cancer Key Companies
17. Endometrial Cancer Key Products
18. Endometrial Cancer – Unmet Needs
19. Endometrial Cancer – Market Drivers and Barriers
20. Endometrial Cancer – Future Perspectives and Conclusion
21. Endometrial Cancer Analyst Views
22. Endometrial Cancer Key Companies
23. Appendix

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: https://www.delveinsight.com/report-store/endometrial-cancer-pipeline-insight
Country: United States
Website: https://www.delveinsight.com/report-store/endometrial-cancer-pipeline-insight